Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
CytomX Therapeutics (CTMX) reported its 2024 financial results, highlighting progress in its clinical pipeline. The company's lead program, CX-2051, a PROBODY Topo-1 ADC targeting EpCAM in advanced colorectal cancer, is advancing with initial Phase 1a data expected in 1H 2025. The Phase 1 study is currently at the seventh dose level.
Financial highlights include total revenue of $138.1 million for 2024, up from $101.2 million in 2023, driven by research program collaborations. The company ended 2024 with $100.6 million in cash and investments. Operating expenses increased to $113.1 million from $107.7 million, primarily due to a $5.0 million milestone payment to AbbVie.
In January 2025, CytomX announced a 40% workforce reduction to focus resources on CX-2051. The company's cash runway extends into Q2 2026. A new $5 million milestone payment was triggered in February 2025 from the Astellas collaboration.
CytomX Therapeutics (Nasdaq: CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference.
The company's CEO and chairman, Sean McCarthy, D.Phil., is scheduled to deliver a presentation on Wednesday, March 12, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of CytomX's website at www.cytomx.com.
Additionally, the management team will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX), a company specializing in masked, conditionally activated biologic therapeutics, has scheduled the release of its fourth quarter and full year 2024 financial results for March 6, 2025, after U.S. markets close.
The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT on the same day. Interested participants can access the webcast through CytomX's investor relations website and are advised to register at least 10 minutes before the call begins.
CytomX Therapeutics (Nasdaq: CTMX), a pioneering company in masked, conditionally activated biologics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean McCarthy, D.Phil., the company's CEO and chairman, is scheduled to deliver a presentation on Wednesday, January 15, 2025, at 1:30 p.m. PT.
The presentation will be accessible through a live webcast on the Events and Presentations section of CytomX's website. Additionally, the management team will be available for individual meetings with registered conference investors.
CytomX Therapeutics (NASDAQ: CTMX) has announced its 2025 strategic pipeline priorities, focusing primarily on CX-2051, their lead wholly-owned EpCAM PROBODY ADC program for advanced metastatic colorectal cancer. Initial Phase 1a clinical data is expected in H1 2025.
The company is implementing significant organizational changes, including a 40% reduction in headcount, primarily affecting non-partnered early research and administrative functions. These changes, along with focused clinical development priorities, are expected to extend their cash runway into Q2 2026. As of Q3 2024, the company had $117.6 million in cash and investments.
Three main clinical programs are in progress: CX-2051 (currently in sixth dose escalation cohort), CX-904 (enrolled over 70 patients), and CX-801 (Phase 1 dose escalation in metastatic melanoma). The company maintains research collaborations with Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron.
CytomX Therapeutics (CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Sean McCarthy, CEO and chairman, will engage in a fireside chat on December 4, 2024, at 8:00 a.m. ET. The presentation will be accessible via live webcast on CytomX's website. The company's management team will also be available for individual meetings with registered conference investors.
CytomX Therapeutics reported Q3 2024 financial results and pipeline updates. Revenue increased to $33.4 million from $26.4 million year-over-year. Cash position stood at $117.6 million as of September 30, 2024. The company's clinical pipeline progresses with three key programs: CX-904 (EGFR-CD3 T-cell engager) advancing in Phase 1a, CX-2051 (EpCAM ADC) in fifth dose escalation cohort for colorectal cancer, and CX-801 (interferon alpha-2b) initiating Phase 1 trials. Initial data for CX-2051 and CX-801 are expected in first half and second half of 2025, respectively.
CytomX Therapeutics (CTMX) has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. Investors can access the webcast through CytomX's investor relations website, and an archived version will be available afterward.
CytomX Therapeutics (Nasdaq: CTMX) has announced the dosing of the first patient with CX-801 in a Phase 1 study for solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine designed to target both immune-oncology sensitive and insensitive tumors. The study (NCT06462794) will evaluate CX-801 as monotherapy and in combination with Merck's KEYTRUDA® (pembrolizumab).
The trial will focus on patients with advanced melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma. CytomX aims to leverage its conditional activation platform to enhance interferon's therapeutic index, potentially making it a key component in immuno-oncology combination therapies.
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference: Scheduled for September 11, 2024, in New York, NY. CytomX will give a formal presentation at 12:30 p.m. ET.
2. 2024 Cantor Global Healthcare Conference: Set for September 19, 2024, also in New York, NY. The company will participate in a fireside chat at 9:45 a.m. ET.
Live webcasts of both events will be available on CytomX's website. The company's management will also be available for one-on-one meetings with registered conference attendees.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
